Navigation Links
Rheumatologists in the EU5 Give the Highest Satisfaction and Performance Ratings to Rituxan and Benlysta for the Treatment of Systemic Lupus Erythematosus (SLE)
Date:8/8/2013

EXTON, Pa., Aug. 8, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that rheumatologists in the EU5 countries (France, Germany, Italy, Spain, United Kingdom) give Genentech/Biogen Idec's Rituxan and GlaxoSmithKline/Human Genome Sciences's Benlysta the highest satisfaction and overall product performance ratings. Despite their lower utilization and later use in the treatment algorithm for moderate-to-severe patients, physicians report positive impressions of the drugs. Surveyed rheumatologists also believe the products outperform other agents on their ability to put the disease into remission, maintain remission and stop organ dysfunction or failure. These attributes are rated as the most important attributes when making the prescribing decision and are partially responsible for driving physicians' high ratings of the products. Surveyed rheumatologists also perceive Rituxan and Benlysta to be well-tolerated with few serious adverse events.

The TreatmentTrends®: Systemic Lupus Erythematosus (EU) report finds that biologic agents are reserved for moderate-to-severe cases of SLE. Although Rituxan is not approved to treat SLE, it is the biologic market leader in the EU5 capturing a 61 percent biologic patient share, followed by Benlysta (26 percent) and Bristol Myers Squibb's Orencia (14 percent). 

Benlysta received approval from the European Medicines Agency in July 2011. However, according to some rheumatologists participating in the study, Benlysta does not have full market approval or was not on protocol in their respective geographic locations. This was the number one reason mentioned for not trying the product. 

"Even though rheumatologists rated Rituxan and Benlysta relatively favorably, and higher than  generic hydroxychloroquine in terms of satisfaction and overall product performance, hydroxychloroquine is still the agent used most often to treat SLE, because it is a relatively low cost product that is easy to use, with moderate efficacy and a good safety profile," said BioTrends Senior Director Greta Unger. "Despite the favorable ratings for Rituxan and Benlysta, rheumatologists are still looking for new agents for their patients with moderate-to-severe SLE, especially the more difficult-to-treat patients with organ damage, such as those with CNS and renal manifestations."

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Though Over One-Third of Rheumatologists Have Prescribed Xeljanz for Their Rheumatoid Arthritis Patients, Physicians are Still Concerned With the Drugs Limited Post-Marketing Experience and Risks of Infection and Malignancy
2. U.S. and European Rheumatologists Agree That a Therapys Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis
3. Inaugural Harris Poll Physician Pulse(SM) Study: Viagra® and Cialis® are Highest Ranked in Trust
4. Intelsius Launches Highest Performing Products
5. Elsevier / Gold Standards Kay Morgan Awarded NCPCP Highest Honor
6. Kaiser Permanente Ranks Highest in 2012 J.D. Power and Associates Employer Satisfaction Study for Second Year in a Row
7. Maximum-Strength Formulation Offers Highest Concentration and Purity
8. Food Recalls Rise to Four a Day in Third Quarter, Reaching Highest Level of Activity in Eight Quarters, According to the ExpertRECALL Index
9. Intelsius Adds to Highest Performing Products
10. U.S. Physicians Report Diabetic Nephropathy as the Renal Condition with the Highest Unmet Need for Treatment
11. MedicalBillersandcoders.com Caters to the Highest Number of Radiologists in Ohio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... IRVING, Texas , Oct. 11, 2017  Caris ... science focused on fulfilling the promise of precision medicine, ... Institute has joined Caris, Precision Oncology Alliance™ (POA) as ... leading cancer centers, the St. Jude Crosson Cancer Institute ... to advance the use of tumor profiling, making cancer ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
Breaking Medicine Technology:
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
(Date:10/12/2017)... ... 12, 2017 , ... On Saturday, October 21, the Health & Wellness Center ... to raise money for the American Heart Association Heart Walk. Teams of up to ... together to keep their treadmills moving for 5 hours. Treadmills will start at 7:00 ...
Breaking Medicine News(10 mins):